tyramine has been researched along with spiperone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Gessa, G; Vaccari, A | 1 |
| Becú-Villalobos, D; Libertun, C; Vacas, MI | 1 |
| Fu, D; Javitch, JA; Lin, H; Strange, PG; Wilson, J | 1 |
4 other study(ies) available for tyramine and spiperone
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[3H]tyramine binding: a comparison with neuronal [3H]dopamine uptake and [3H]mazindol binding processes.
Topics: Animals; Cattle; Corpus Striatum; Dopamine; Hypothyroidism; Indoles; Male; Mazindol; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Tyramine | 1989 |
Prolactin inhibition by p-tyramine in the male rat: site of action.
Topics: Animals; In Vitro Techniques; Male; Morphine; Octopamine; Pituitary Gland, Anterior; Prolactin; Rats; Receptors, Dopamine; Secretory Rate; Serotonin Antagonists; Spiperone; Stress, Psychological; Thyrotropin-Releasing Hormone; Time Factors; Tyramine | 1987 |
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
Topics: 1-Methyl-3-isobutylxanthine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Binding, Competitive; Bromocriptine; Butaclamol; Chlorpromazine; CHO Cells; Clozapine; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; GTP-Binding Proteins; Haloperidol; Humans; Macromolecular Substances; Mutagenesis, Site-Directed; Phenethylamines; Piperidines; Protein Binding; Protein Conformation; Radioligand Assay; Receptors, Dopamine D2; Recombinant Fusion Proteins; Sodium; Spiperone; Structure-Activity Relationship; Sulpiride; Transfection; Tyramine | 2001 |